Local organizations, researchers continue to win CPRIT funding In addition to hosting clinical trials, MD Anderson also continued to secure CPRIT funding. The cancer research center was awarded ...

Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the ...

Discover how the University of Texas MD Anderson Cancer Center has enhanced patient experience with five new initiatives, including a pre-intake navigation ...

Called cryoablation, the procedure has not been federally approved for breast cancer treatment, but clinical trials are ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

Under the agreements, AmMax and MD Anderson will build upon preclinical discoveries made by MD Anderson researchers to evaluate the potential for AMB-066, which targets colony stimulating factor 1 ...

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive ...

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer ...

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical trial ...

It’s her room at the University of Texas MD ... at MD Anderson for a video. HOPE FOR A VACCINE: A breakthrough in cancer vaccines may be coming, and Houston is a hub for clinical trials ...

About Bladder Cancer More than 83,000 people are estimated to be diagnosed with bladder cancer in 2024. NMIBC is the most common form of bladder cancer, representing approximately 75% of newly ...